Senti Biosciences Holdings, Inc. Financials
This page shows Senti Biosciences Holdings, Inc. (SNTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Senti remains a cash-burning development-stage platform, where research spending and financing matter far more than reported revenue.
From FY2023 to FY2025, operating cash burn improved only modestly, from-$52.4M to-$43.4M , so the cost base remained largely intact despite almost no commercial revenue. Because cash is now$16.4M and equity only$5.6M , new financing appears to be extending runway rather than building a self-funding business.
FY2025 reads like a pre-commercial cost structure: revenue was only
The liquidity cushion has narrowed as cash fell from
Financial Health Signals
We are recalculating Senti Biosciences Holdings, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Senti Biosciences Holdings, Inc. scores -13.60, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($31.1M) relative to total liabilities ($45.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Senti Biosciences Holdings, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Senti Biosciences Holdings, Inc. generates $0.71 in operating cash flow (-$43.4M OCF vs -$61.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Senti Biosciences Holdings, Inc. generated $22K in revenue in fiscal year 2025.
Senti Biosciences Holdings, Inc.'s EBITDA was -$65.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.9% from the prior year.
Senti Biosciences Holdings, Inc. reported -$61.4M in net income in fiscal year 2025. This represents a decrease of 16.4% from the prior year.
Senti Biosciences Holdings, Inc. earned $-2.73 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Senti Biosciences Holdings, Inc. generated -$43.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 5.4% from the prior year.
Senti Biosciences Holdings, Inc. held $16.4M in cash against $0 in long-term debt as of fiscal year 2025.
Senti Biosciences Holdings, Inc. had 31M shares outstanding in fiscal year 2025.
Margins & Returns
Senti Biosciences Holdings, Inc.'s operating margin was -312631.8% in fiscal year 2025, reflecting core business profitability.
Senti Biosciences Holdings, Inc.'s net profit margin was -279263.6% in fiscal year 2025, showing the share of revenue converted to profit.
Senti Biosciences Holdings, Inc.'s ROE was -1099.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 893.5 percentage points from the prior year.
Capital Allocation
Senti Biosciences Holdings, Inc. invested $37.6M in research and development in fiscal year 2025. This represents an increase of 9.4% from the prior year.
Senti Biosciences Holdings, Inc. invested $196K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 653.8% from the prior year.
SNTI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16K | N/A | N/A | N/A | $0 | N/A | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.3M | N/A | $10.5M+4.9% | $10.0M+8.1% | $9.3M | N/A | $8.7M-5.4% | $9.2M |
| SG&A Expenses | $6.2M | N/A | $6.4M-5.0% | $6.8M-4.9% | $7.1M | N/A | $6.6M+56.0% | $4.2M |
| Operating Income | -$4.6M | N/A | -$16.9M-0.9% | -$16.8M-2.4% | -$16.4M | N/A | -$15.2M-13.9% | -$13.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$4.2M | N/A | -$18.1M-23.0% | -$14.7M-4.4% | -$14.1M | N/A | -$28.9M-157.7% | -$11.2M |
| EPS (Diluted) | $-0.14 | N/A | $-0.69-23.2% | $-0.56+60.3% | $-1.41 | N/A | $-6.31-157.6% | $-2.45 |
SNTI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.2M-25.3% | $51.2M-2.8% | $52.7M-23.1% | $68.5M-17.2% | $82.8M-15.4% | $97.8M+69.5% | $57.7M-33.6% | $86.9M |
| Current Assets | $14.8M-36.5% | $23.3M+28.2% | $18.2M-44.2% | $32.5M-28.1% | $45.2M-23.3% | $59.0M+239.2% | $17.4M-60.8% | $44.3M |
| Cash & Equivalents | $8.9M-45.6% | $16.4M+34.1% | $12.2M-43.3% | $21.6M-36.2% | $33.8M-30.0% | $48.3M+360.7% | $10.5M-33.9% | $15.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $172K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $35.7M-21.8% | $45.6M+2.4% | $44.6M+1.5% | $43.9M-2.3% | $44.9M-37.8% | $72.2M+73.0% | $41.7M-2.4% | $42.8M |
| Current Liabilities | $14.3M+2.1% | $14.0M+16.2% | $12.0M+20.4% | $10.0M-6.9% | $10.7M-18.4% | $13.1M+45.0% | $9.1M0.0% | $9.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.6M-54.1% | $5.6M-31.2% | $8.1M-67.1% | $24.7M-34.9% | $37.9M+47.6% | $25.6M+60.4% | $16.0M-63.8% | $44.1M |
| Retained Earnings | -$362.8M-1.2% | -$358.6M-4.2% | -$344.1M-5.6% | -$326.0M-4.7% | -$311.2M-4.7% | -$297.1M-0.2% | -$296.5M-10.8% | -$267.7M |
SNTI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.5M-8.8% | -$6.9M+27.2% | -$9.4M+27.7% | -$13.1M+7.0% | -$14.1M-4.0% | -$13.5M-71.7% | -$7.9M+5.7% | -$8.3M |
| Capital Expenditures | N/A | $0 | $0-100.0% | $196K | $0-100.0% | $11K | $0 | $0 |
| Free Cash Flow | N/A | -$6.9M+27.2% | -$9.4M+28.8% | -$13.3M+5.6% | -$14.1M-4.0% | -$13.5M-71.8% | -$7.9M+5.7% | -$8.3M |
| Investing Cash Flow | $114K | $0 | $0+100.0% | -$184K | $0+100.0% | -$11K-118.3% | $60K | $0 |
| Financing Cash Flow | -$118K-101.1% | $11.0M+8803.2% | $124K-87.7% | $1.0M+344.2% | -$414K-100.8% | $51.3M+2002.0% | $2.4M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SNTI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -28850.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -26381.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -164.6% | N/A | -223.2%-163.4pp | -59.8%-22.5pp | -37.3% | N/A | -180.5%-155.1pp | -25.4% |
| Return on Assets | -11.0% | N/A | -34.4%-12.9pp | -21.5%-4.4pp | -17.1% | N/A | -50.0%-37.1pp | -12.9% |
| Current Ratio | 1.04-0.6 | 1.67+0.2 | 1.51-1.7 | 3.26-1.0 | 4.22-0.3 | 4.49+2.6 | 1.92-3.0 | 4.89 |
| Debt-to-Equity | 13.91+5.7 | 8.16+2.7 | 5.49+3.7 | 1.78+0.6 | 1.19-1.6 | 2.81+0.2 | 2.61+1.6 | 0.97 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Senti Biosciences Holdings, Inc.'s annual revenue?
Senti Biosciences Holdings, Inc. (SNTI) reported $22K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Senti Biosciences Holdings, Inc. profitable?
No, Senti Biosciences Holdings, Inc. (SNTI) reported a net income of -$61.4M in fiscal year 2025, with a net profit margin of -279263.6%.
What is Senti Biosciences Holdings, Inc.'s EBITDA?
Senti Biosciences Holdings, Inc. (SNTI) had EBITDA of -$65.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Senti Biosciences Holdings, Inc.'s operating margin?
Senti Biosciences Holdings, Inc. (SNTI) had an operating margin of -312631.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Senti Biosciences Holdings, Inc.'s net profit margin?
Senti Biosciences Holdings, Inc. (SNTI) had a net profit margin of -279263.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Senti Biosciences Holdings, Inc.'s return on equity (ROE)?
Senti Biosciences Holdings, Inc. (SNTI) has a return on equity of -1099.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Senti Biosciences Holdings, Inc.'s free cash flow?
Senti Biosciences Holdings, Inc. (SNTI) generated -$43.6M in free cash flow during fiscal year 2025. This represents a -5.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Senti Biosciences Holdings, Inc.'s operating cash flow?
Senti Biosciences Holdings, Inc. (SNTI) generated -$43.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Senti Biosciences Holdings, Inc.'s total assets?
Senti Biosciences Holdings, Inc. (SNTI) had $51.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Senti Biosciences Holdings, Inc.'s capital expenditures?
Senti Biosciences Holdings, Inc. (SNTI) invested $196K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Senti Biosciences Holdings, Inc. spend on research and development?
Senti Biosciences Holdings, Inc. (SNTI) invested $37.6M in research and development during fiscal year 2025.
What is Senti Biosciences Holdings, Inc.'s current ratio?
Senti Biosciences Holdings, Inc. (SNTI) had a current ratio of 1.67 as of fiscal year 2025, which is generally considered healthy.
What is Senti Biosciences Holdings, Inc.'s debt-to-equity ratio?
Senti Biosciences Holdings, Inc. (SNTI) had a debt-to-equity ratio of 8.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Senti Biosciences Holdings, Inc.'s return on assets (ROA)?
Senti Biosciences Holdings, Inc. (SNTI) had a return on assets of -119.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Senti Biosciences Holdings, Inc.'s cash runway?
Based on fiscal year 2025 data, Senti Biosciences Holdings, Inc. (SNTI) had $16.4M in cash against an annual operating cash burn of $43.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Senti Biosciences Holdings, Inc.'s Altman Z-Score?
Senti Biosciences Holdings, Inc. (SNTI) has an Altman Z-Score of -13.60, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Senti Biosciences Holdings, Inc.'s Piotroski F-Score?
Senti Biosciences Holdings, Inc. (SNTI) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Senti Biosciences Holdings, Inc.'s earnings high quality?
Senti Biosciences Holdings, Inc. (SNTI) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.